GUCY1A2 Antibody

What is GUCY1A2 and what cellular functions does it perform?

GUCY1A2 (Guanylate Cyclase 1, Soluble, alpha 2) is a gene encoding the alpha-2 subunit of soluble guanylate cyclase (sGC), a heterodimeric protein consisting of alpha and beta subunits. This enzyme plays a crucial role in the nitric oxide (NO) signaling pathway by catalyzing the conversion of GTP to the second messenger cyclic guanosine monophosphate (cGMP). The sGC functions as the main receptor for nitric oxide and nitrovasodilator drugs, mediating important physiological processes including vasodilation, neurotransmission, and platelet inhibition . Recent research has also implicated GUCY1A2 in tumorigenesis and cancer progression, particularly in gastric cancer where its overexpression correlates with poor prognosis .

What types of GUCY1A2 antibodies are currently available for research?

Several types of GUCY1A2 antibodies are available for research applications, varying in their target epitopes, host species, and conjugation status:

• Polyclonal antibodies targeting specific amino acid regions (e.g., AA 105-136, AA 128-177, AA 296-401, AA 699-732)

• Antibodies targeting different domains (N-terminal vs. C-terminal regions)

• Unconjugated antibodies for standard applications

• Conjugated antibodies (e.g., biotin or APC-conjugated) for specialized applications

• Antibodies raised in different host species (primarily rabbit, some in mouse)

Most commercially available GUCY1A2 antibodies are polyclonal, generated in rabbits immunized with KLH-conjugated synthetic peptides from various regions of human GUCY1A2 .

What are the common applications for GUCY1A2 antibodies?

GUCY1A2 antibodies have diverse applications in molecular and cellular research:

• Western blotting (WB) for protein expression analysis and quantification

• Immunohistochemistry (IHC) for tissue localization studies, including paraffin-embedded section analysis

• Enzyme-linked immunosorbent assay (ELISA) for quantitative protein detection

• Immunocytochemistry (ICC) for cellular localization studies

• Immunofluorescence (IF) for visualization of protein distribution within cells

These applications enable researchers to investigate GUCY1A2 expression, localization, and function in various experimental systems, from cell cultures to tissue specimens .

How should researchers select the optimal GUCY1A2 antibody epitope for different experimental objectives?

Selection of the optimal epitope depends on your specific research objectives:

For structural and functional studies: Antibodies targeting functional domains like the catalytic region are preferable. For instance, antibodies targeting amino acids 699-732 may be more suitable for investigating enzyme activity as this region is associated with the catalytic domain .

For interaction studies: If investigating protein-protein interactions, select antibodies targeting regions outside known interaction domains to avoid epitope masking. N-terminal targeting antibodies (AA 105-136) are often useful for co-immunoprecipitation studies .

For species-comparative studies: Choose antibodies targeting highly conserved regions across species. Several GUCY1A2 antibodies show cross-reactivity between human, mouse, and rat samples, particularly those targeting the N-terminal region .

For specificity concerns: Consider epitopes with minimal homology to other guanylate cyclase family members (especially GUCY1A1) to ensure specificity. Custom antibodies targeting unique regions may be necessary for highly specific applications .

What methodological challenges exist when using GUCY1A2 antibodies in cancer research, and how can they be addressed?

Cancer research with GUCY1A2 antibodies presents several methodological challenges:

Heterogeneous expression: GUCY1A2 expression can vary significantly within tumor samples. This challenge can be addressed by using tissue microarrays with multiple tumor cores and quantitative imaging analysis to account for heterogeneity .

Cross-reactivity concerns: GUCY1A2 shares homology with other guanylate cyclase family members. Researchers should validate antibody specificity through knockout/knockdown controls or by using multiple antibodies targeting different epitopes to confirm findings .

Correlation with activational state: Standard antibodies detect total GUCY1A2 but not its activation state. For functional studies, researchers should complement antibody-based detection with enzymatic activity assays or phospho-specific antibodies if available .

Tissue fixation effects: Formalin fixation can mask epitopes. Optimization of antigen retrieval methods (heat-induced vs. enzymatic) is crucial for immunohistochemical applications in cancer tissues .

Validation in clinical samples: When studying GUCY1A2 as a prognostic marker, validation in independent patient cohorts is essential. The combination of qRT-PCR data with protein-level detection strengthens findings, as demonstrated in studies of gastric cancer patients .

How can researchers effectively distinguish between GUCY1A2 and other guanylate cyclase subunits in complex biological samples?

Distinguishing between guanylate cyclase subunits requires careful methodological approaches:

Antibody selection: Choose antibodies targeting unique regions with minimal sequence homology to other subunits. Antibodies targeting the N-terminal region (AA 105-136) of GUCY1A2 often provide better specificity compared to those targeting conserved catalytic domains .

Multiple detection methods: Combine immunological techniques with molecular approaches such as:

• RT-PCR with subunit-specific primers

• RNA interference with subunit-specific siRNAs as controls

• Multiple antibodies targeting different epitopes of the same protein

Sequential immunoprecipitation: For samples containing multiple guanylate cyclase isoforms, perform sequential immunoprecipitation with antibodies against other subunits first, followed by GUCY1A2 detection in the remaining fraction .

Mass spectrometry validation: For definitive identification, immunoprecipitated samples can be analyzed by mass spectrometry to confirm the identity of the detected protein based on unique peptide sequences .

Western blotting optimization: Use gradient gels (4-15%) to better separate different guanylate cyclase subunits based on their molecular weights, and include positive and negative control samples .

What are the optimal conditions for using GUCY1A2 antibodies in Western blotting?

For optimal Western blotting with GUCY1A2 antibodies, consider the following protocol adaptations:

Sample preparation:

• Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors for complete extraction

• Include 1mM DTT to maintain protein reduction state

• Sonication may be required to fully solubilize membrane-associated GUCY1A2

Gel electrophoresis:

• 8% SDS-PAGE gels are optimal for resolving GUCY1A2 (molecular weight ~82 kDa)

• Load 30-50 μg of total protein per lane for cell lysates

• Include positive control lysates from tissues known to express GUCY1A2 (brain or lung tissue)

Transfer and blocking:

• PVDF membranes are preferred over nitrocellulose for better protein retention

• Transfer at 30V overnight at 4°C for large proteins like GUCY1A2

• Block with 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature

Antibody incubation:

• Primary antibody dilution: typically 1:500 to 1:1000 in 5% BSA in TBST

• Incubate primary antibody overnight at 4°C

• Secondary antibody: anti-rabbit HRP at 1:2000 to 1:5000 for 1 hour at room temperature

Detection:

• Enhanced chemiluminescence (ECL) detection systems work well

• For quantitative analysis, consider fluorescence-based detection methods

What controls should be included when validating GUCY1A2 antibodies for new applications?

Comprehensive validation of GUCY1A2 antibodies requires multiple controls:

Positive controls:

• Tissue/cell lysates known to express GUCY1A2 (brain, lung, or specific cell lines)

• Recombinant GUCY1A2 protein for antibody calibration

• Overexpression systems with GUCY1A2 plasmids

Negative controls:

• GUCY1A2 knockout or knockdown samples

• Tissues known to express minimal GUCY1A2

• Primary antibody omission control

• Isotype control antibodies to assess non-specific binding

Specificity controls:

• Peptide competition assays using the immunizing peptide

• Detection with multiple antibodies targeting different GUCY1A2 epitopes

• Parallel detection of other guanylate cyclase subunits to assess cross-reactivity

Application-specific controls:

• For IHC: Include isotype controls on serial sections

• For ICC/IF: Include secondary-only controls to assess background

• For IP experiments: Include IgG control immunoprecipitations

The complete validation should include multiple experimental techniques (e.g., Western blot, IHC, and qRT-PCR) to confirm consistency across different detection methods .

How can researchers optimize immunohistochemistry protocols for GUCY1A2 detection in tissue samples?

Optimizing immunohistochemistry for GUCY1A2 requires careful attention to several parameters:

Tissue preparation:

• Fixation: 10% neutral buffered formalin for 24 hours is standard

• Section thickness: 4-5 μm sections are optimal for balanced sensitivity and resolution

• Freshly cut sections perform better than stored slides

Antigen retrieval:

• Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes

• For difficult samples, try alternative buffers like Tris-EDTA (pH 9.0)

• Allow slides to cool slowly to room temperature after heating

Blocking steps:

• Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

• Block non-specific binding with 5% normal goat serum for 1 hour

• For tissues with high background, consider additional avidin/biotin blocking

Antibody conditions:

• Dilution: Start with 1:100 and optimize through titration

• Incubation: Overnight at 4°C in a humidified chamber

• Diluent: Use antibody diluent with background reducing components

Detection systems:

• For higher sensitivity, use polymer-based detection systems

• Chromogen development time should be standardized (typically 5-10 minutes with DAB)

• Counterstain with hematoxylin for 30-60 seconds for nuclear contrast

Troubleshooting high background:

• Increase washing steps (3-5 times, 5 minutes each)

• Reduce primary antibody concentration

• Consider using automated staining platforms for consistent results

How does GUCY1A2 expression correlate with clinical outcomes in cancer research?

Research has demonstrated significant correlations between GUCY1A2 expression and clinical outcomes in cancer:

Expression patterns in cancer:

• GUCY1A2 is significantly overexpressed in gastric cancer tissues compared to adjacent non-cancerous tissues (p < 0.001)

• This overexpression has been validated through multiple methodologies including qRT-PCR and meta-analysis of GEO datasets (SMD = 0.65, 95% CI: 0.20-1.10)

Correlation with clinicopathological features:

• High GUCY1A2 expression correlates with poor histological grade (OR=1.858 for poor vs. well or moderate, p = 0.004)

• Advanced T stage is associated with increased GUCY1A2 expression (OR = 3.389 for T3 vs. T1, p = 0.025; OR = 3.422 for T4 vs. T1, p = 0.028)

Prognostic significance:

Pathway associations:

• Gene set enrichment analysis (GSEA) indicates that high GUCY1A2 expression phenotypes are enriched in tumor-associated signaling pathways

• These findings suggest GUCY1A2 may be a promising prognostic biomarker for gastric cancer and potentially other malignancies

What are the best approaches for quantifying GUCY1A2 protein levels in comparative studies?

For accurate quantification of GUCY1A2 protein levels in comparative studies, researchers should consider:

Western blot quantification:

• Use internal loading controls (β-actin, GAPDH, or vinculin) for normalization

• Implement digital image analysis with dedicated software (ImageJ, Image Lab)

• Ensure signals fall within the linear range of detection

• Run a standard curve using recombinant GUCY1A2 at known concentrations

ELISA-based quantification:

• Commercial or custom sandwich ELISA provides more precise quantification

• Standard curves must use the same recombinant protein as calibrators

• Use technical triplicates to assess measurement precision

• Validate findings across multiple sample types

Immunohistochemistry quantification:

• Use digital pathology software for objective scoring

• Implement H-score methodology (intensity × percentage of positive cells)

• Consider the subcellular localization in the scoring system

• Use automated tissue microarray analysis for high-throughput studies

Multiplex approaches:

• For co-expression studies, consider multiplex immunofluorescence

• Mass cytometry or imaging mass cytometry can provide highly multiplexed protein quantification

• Normalize GUCY1A2 expression to multiple housekeeping proteins for robust comparisons

Internal validation:

• Cross-validate protein quantification with mRNA levels when possible

• Consider absolute quantification methods for more precise comparisons

• Include biological replicates to account for natural variation

How can researchers distinguish between normal physiological functions and pathological roles of GUCY1A2 in their studies?

Distinguishing between physiological and pathological roles of GUCY1A2 requires strategic experimental approaches:

Contextual expression analysis:

• Compare expression levels across a spectrum from normal to pathological tissues

• Analyze expression in developmental stages to establish baseline physiological patterns

• Use tissue-specific knockout or transgenic models to identify context-dependent functions

Functional assays:

• Measure cGMP production as a functional readout of normal GUCY1A2 activity

• Compare enzyme kinetics (Km, Vmax) between normal and pathological samples

• Assess response to physiological stimuli (NO donors) versus pathological conditions

Signaling pathway analysis:

• Investigate downstream effectors like protein kinase G (PKG) activation

• Use pathway inhibitors to distinguish normal from aberrant signaling cascades

• Perform phosphoproteomic analysis to identify altered signaling networks

Integration with clinical parameters:

• Correlate expression levels with disease progression metrics

• Develop multi-parameter models incorporating other biomarkers

• Longitudinal studies to track changes during disease progression

Interaction studies:

• Investigate altered binding partners in disease states using co-immunoprecipitation

• Assess heterodimer formation with beta subunits in normal versus pathological conditions

• Study subcellular localization changes that may indicate pathological functions

What are common technical issues encountered with GUCY1A2 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with GUCY1A2 antibodies:

Non-specific bands in Western blotting:

• Issue: Multiple bands appearing at unexpected molecular weights

• Solution: Optimize antibody dilution (typically 1:500-1:1000), increase washing stringency, and use gradient gels for better resolution. Consider using alternative antibodies targeting different epitopes to confirm specificity .

Poor signal in immunohistochemistry:

• Issue: Weak or absent staining despite confirmed expression

• Solution: Optimize antigen retrieval methods (try both citrate and EDTA-based buffers), extend primary antibody incubation time (overnight at 4°C), and use signal amplification systems like polymer-HRP detection .

High background in immunofluorescence:

• Issue: Non-specific fluorescence obscuring specific signals

• Solution: Use more stringent blocking (5% BSA with 0.3% Triton X-100), include background reducing agents in antibody diluent, and optimize secondary antibody concentration. Consider autofluorescence quenching for tissues with high natural fluorescence .

Inconsistent results between applications:

• Issue: Antibody works in one application but not in others

• Solution: Different applications require different epitope accessibility. Try antibodies targeting different regions of GUCY1A2, as some epitopes may be masked in certain applications. Always validate antibodies for each specific application .

Batch-to-batch variability:

• Issue: Inconsistent results between antibody lots

• Solution: Purchase larger amounts of a single lot for long-term studies, perform lot-specific validation, and maintain reference samples to calibrate between batches .

How should researchers interpret conflicting data between GUCY1A2 protein expression and mRNA levels?

Discrepancies between GUCY1A2 protein and mRNA levels are not uncommon and require careful interpretation:

Potential mechanisms for discrepancies:

• Post-transcriptional regulation: miRNAs may regulate GUCY1A2 translation without affecting mRNA levels

• Protein stability differences: Altered protein degradation rates in different tissues or disease states

• Technical considerations: Different detection sensitivities between protein and mRNA quantification methods

Validation approaches:

• Use multiple antibodies targeting different epitopes to confirm protein expression findings

• Implement absolute quantification methods for both protein (SRM/MRM mass spectrometry) and mRNA (digital PCR)

• Investigate protein half-life using cycloheximide chase experiments compared to mRNA stability

Biological interpretation:

• Temporal dynamics: Consider time-course studies to identify delayed protein expression relative to mRNA induction

• Compartmentalization: Assess subcellular localization changes that may occur without total protein level changes

• Functional readouts: Measure enzymatic activity (cGMP production) to determine if protein expression correlates with function

Integration strategies:

• Develop correction factors based on systematic analyses of mRNA-protein correlations

• Use proteogenomic approaches to integrate transcriptomic and proteomic data

• Consider multi-omics analyses to identify regulatory mechanisms explaining discrepancies

What are the considerations for using GUCY1A2 antibodies in multi-species comparative studies?

When conducting multi-species comparative studies with GUCY1A2 antibodies, researchers should consider:

Sequence homology analysis:

• Human GUCY1A2 shares approximately 90% amino acid sequence identity with mouse and 88% with rat orthologs

• Certain domains show higher conservation than others, making them better targets for cross-species studies

• Antibodies targeting conserved regions (often in the catalytic domain) have higher likelihood of cross-reactivity

Experimental validation:

• Always validate antibodies separately in each species using positive and negative controls

• Blocking peptide competition assays with species-specific peptides can confirm specificity

• Western blotting with recombinant proteins from each species provides definitive validation

Application-specific considerations:

• For IHC/IF: Optimize fixation and antigen retrieval protocols separately for each species

• For WB: Be aware of species-specific post-translational modifications that may alter migration patterns

• For IP: Binding affinity may vary between species, requiring optimization of antibody amounts

Species-matched secondary antibodies:

• Use secondary antibodies raised specifically against the species of the primary antibody

• For multiplex studies, carefully select secondary antibodies to avoid cross-reactivity

• Consider directly conjugated primary antibodies for multi-species work to eliminate secondary antibody concerns

Quantitative comparisons:

• Avoid direct quantitative comparisons between species using the same antibody

• Establish species-specific standard curves when possible

• Use relative quantification within each species rather than absolute comparisons across species